BioSpace News Archive

STS101 EMERGE™ Phase 3 efficacy trial remains on track with announcement of topline data expected in second half of 2020

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, reported financial results for the three months ended March 31, 2020, and provided a corporate update.

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, announced the closing of its initial public offering of 3,666,667 shares of common stock at a public offering price of $15.00 per share.

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced first quarter results and provided a corporate update.

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced financial results for the first quarter ended March 31, 2020 and provided a corporate update.

Translate Bio announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the Bank of America Securities Virtual 2020 Health Care Conference on Thursday, May 14, 2020, at 9:00 a.m. ET.

Cyclacel Pharmaceuticals, Inc. reported its financial results for the first quarter 2020 and business highlights, including an update on its progress with fadraciclib, Cyclacel’s novel CDK inhibitor.

KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, reported its financial results for the first quarter ended March 31, 2020.

NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced that management will present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19 at 3:00 p.m. ET/12:00 p.m. PT.

Syndax Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 6,388,889 shares of its common stock at a price to the public of $18.00 per share.